CROSSJECT (ALCJ.PA) Stock Overview
Europe - EPA:ALCJ - FR0011716265 - Common Stock
ALCJ.PA Key Statistics, Chart & Performance
The current stock price of ALCJ.PA is 1.656 EUR. In the past month the price increased by 10.55%. In the past year, price decreased by -31%.
ALCJ.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1EL.MI | ESSILORLUXOTTICA | 39.32 | 123.57B | ||
| EL.PA | ESSILORLUXOTTICA | 38.72 | 121.70B | ||
| ESL.DE | ESSILORLUXOTTICA | 38.72 | 121.70B | ||
| 2U3.DE | ALCON INC | 24.91 | 31.99B | ||
| CBHD.DE | COLOPLAST-B | 29.88 | 16.02B | ||
| AFW.DE | ALIGN TECHNOLOGY INC | 13.76 | 7.98B | ||
| GENT.OL | GENTIAN DIAGNOSTICS ASA | 20.74 | 860.44M | ||
| GBT.PA | GUERBET | 10.14 | 162.80M | ||
| AFME.PA | AFFLUENT MEDICAL SA | N/A | 60.21M | ||
| PTP.DE | PENTIXAPHARM HOLDING AG | N/A | 44.39M | ||
| IVN.MI | IVISION TECH SPA | N/A | 17.48M |
Related stock screener links
About ALCJ.PA
Company Profile
Crossject SA manufactures and markets needle free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte and currently employs 108 full-time employees. The company went IPO on 2014-02-20. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous, and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance, and comfort. The firm has industrial partnerships with Hirtenberger and Recipharm. The company provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Company Info
CROSSJECT
Parc Mazen-Sully, 6 Rue Pauline Kergomard
Dijon BOURGOGNE-FRANCHE-COMTE FR
Employees: 106
Phone: 33380549850
CROSSJECT / ALCJ.PA FAQ
What is the stock price of CROSSJECT today?
The current stock price of ALCJ.PA is 1.656 EUR. The price increased by 3.5% in the last trading session.
What is the ticker symbol for CROSSJECT stock?
The exchange symbol of CROSSJECT is ALCJ and it is listed on the Euronext Paris - Matif exchange.
On which exchange is ALCJ.PA stock listed?
ALCJ.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for CROSSJECT stock?
9 analysts have analysed ALCJ.PA and the average price target is 3.37 EUR. This implies a price increase of 103.26% is expected in the next year compared to the current price of 1.656. Check the CROSSJECT stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CROSSJECT worth?
CROSSJECT (ALCJ.PA) has a market capitalization of 84.79M EUR. This makes ALCJ.PA a Micro Cap stock.
How many employees does CROSSJECT have?
CROSSJECT (ALCJ.PA) currently has 106 employees.
What are the support and resistance levels for CROSSJECT (ALCJ.PA) stock?
CROSSJECT (ALCJ.PA) has a support level at 1.62 and a resistance level at 1.75. Check the full technical report for a detailed analysis of ALCJ.PA support and resistance levels.
Is CROSSJECT (ALCJ.PA) expected to grow?
The Revenue of CROSSJECT (ALCJ.PA) is expected to grow by 308.97% in the next year. Check the estimates tab for more information on the ALCJ.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CROSSJECT (ALCJ.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALCJ.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALCJ.PA, evaluating the profitability, health, valuation and growth aspects
- CROSSJECT (ALCJ.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CROSSJECT (ALCJ.PA) Sales and EPS estimates to see what analysts future expectations are.
- CROSSJECT (ALCJ.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CROSSJECT (ALCJ.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- CROSSJECT (ALCJ.PA) Stock Chart to make your own analysis
- CROSSJECT (ALCJ.PA) Latest news and press-releases to stay up to date.
Does CROSSJECT (ALCJ.PA) stock pay dividends?
ALCJ.PA does not pay a dividend.
When does CROSSJECT (ALCJ.PA) report earnings?
CROSSJECT (ALCJ.PA) will report earnings on 2025-09-22.
What is the Price/Earnings (PE) ratio of CROSSJECT (ALCJ.PA)?
CROSSJECT (ALCJ.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.28).
ALCJ.PA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ALCJ.PA. When comparing the yearly performance of all stocks, ALCJ.PA is a bad performer in the overall market: 88% of all stocks are doing better.
ALCJ.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALCJ.PA. ALCJ.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALCJ.PA Financial Highlights
Over the last trailing twelve months ALCJ.PA reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS decreased by -23.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.53% | ||
| ROE | -470.75% | ||
| Debt/Equity | 6.53 |
ALCJ.PA Forecast & Estimates
9 analysts have analysed ALCJ.PA and the average price target is 3.37 EUR. This implies a price increase of 103.26% is expected in the next year compared to the current price of 1.656.
For the next year, analysts expect an EPS growth of 125.14% and a revenue growth 308.97% for ALCJ.PA